New Data Confirming Broad Spectrum of Basilea's Late-Stage Antifungal, BAL8557, Presented at the ICAAC Conference
29 sept. 2006 01h27 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Sept. 29, 2006 (PRIMEZONE) -- Data presented at ICAAC further support phase III development program scheduled to start by year-end in invasive candida (yeast) and aspergillus...
Basilea Reports 2006 Interim Results Reflecting Successful Investment in Late-stage Development Programs
24 août 2006 01h45 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Aug. 24, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) reports interim financial results. Three compounds planned to be in phase III by year-end.
Highlights of the...
Basilea Presents Compelling Clinical and Preclinical Data on Its Novel Broad-Spectrum Antifungal BAL8557
27 juin 2006 01h44 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, June 27, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) presents data on its antifungal BAL8557 showing a promising safety and drug-drug interaction profile. Additional...
Basilea Completes Patient Recruitment of Alitretinoin Pivotal Phase III Study in Patients With Severe Chronic Hand Dermatitis
17 mai 2006 01h49 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, May 17, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today completion of recruitment of over 1000 patients in its BACH study (Benefit of Alitretinoin in...
Phase III Community-Acquired Pneumonia Study Opens for Basilea's Novel Broad-spectrum Anti-MRSA Antibiotic Ceftobiprole to Broaden Indications
17 mai 2006 01h46 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, May 17, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today the initiation of a community-acquired pneumonia trial further expanding the development program...
FDA Fast Track Designation for Basilea's Novel Broad-Spectrum Water-Soluble Antifungal BAL8557
02 mai 2006 01h31 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, May 2, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that it received fast track designation from the U.S. Food and Drug Administration (FDA) for its...
Basilea Pharmaceutica Ltd. Shareholders Approve All Board of Director Proposals at 2006 Annual General Meeting
28 mars 2006 13h00 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, March 28, 2006 (PRIMEZONE) -- Basilea's (SWX:BSLN) shareholders approved today the annual report, the 2005 financial statements, as well as the release of the members of the Board...
Basilea Announces Positive Phase III Results for Ceftobiprole, its First-In-Class Anti-MRSA Cephalosporin
02 mars 2006 01h37 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, March 2, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. announces today positive results for its first comparative phase III trial with ceftobiprole. Ceftobiprole showed a high...
Basilea Pharmaceutica Ltd. Reports 2005 Financial Results
28 févr. 2006 01h38 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Feb. 28, 2006 (PRIMEZONE) -- Basilea (SWX:BSLN) announced 2005 financial results reflecting positive operating cash flow. Payments from Basilea's license partner, Johnson &...
Basilea Presents Late-breaker Data for its Novel Antifungal Agent BAL8557, Confirming its Broad Spectrum of Activity Including Difficult Yeast and Mold Infections
20 déc. 2005 01h35 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Dec. 20, 2005 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) presents positive phase II clinical trial data on its water-soluble azole BAL8557 in a late-breaker abstract at...